Paradigm Biopharmaceuticals Limited (ASX: PAR)
Sector: Health Care
Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Data as of 30 Sept 2026.
Recent capital raises
Substantial holders — latest moves
| Date | Holder | Move | Holding | Source |
|---|---|---|---|---|
| 12 Nov 2025 | Paul Rennie | Exit | — | Filing ↗ |
| 11 Feb 2025 | Citicorp Nominees Pty Limited | Entry | ?% → 4.42% | Filing ↗ |
| 26 Sept 2024 | Allianz SE and the entities listed in the Appendix A | Exit | — | Filing ↗ |
| 30 Aug 2024 | PAUL RENNIE AND RELATED COMPANIES | Entry | ?% → 5.9% | Filing ↗ |
| 22 May 2024 | Allianz SE and the entities listed in the Appendix A | Decrease | 7.09% → 6.08% | Filing ↗ |
Director trades — on-market
| Date | Director | Trade | Source |
|---|---|---|---|
| 14 Oct 2024 | Matthew James Fry | Bought 200,000 Fully Paid Ordinary Shares | Filing ↗ |
| 10 Oct 2024 | Paul Rennie | Bought 245,300 shares (150,000 on 10 October 2024; 95,300 on 15 October 2024) | Filing ↗ |
| 10 Oct 2024 | Matthew James Fry | Bought 150,000 Fully Paid Ordinary Shares | Filing ↗ |
| 18 May 2023 | HELEN FISHER | Bought 10,204 | Filing ↗ |
| 12 May 2023 | Paul Rennie | Bought 73,851 Fully Paid Ordinary Shares | Filing ↗ |
Cash and runway
Ask about PAR in Claude or ChatGPT
Add the Capital Signal connector at https://capitalsignal.io/api/mcp, then ask:
- Has PAR raised money in the last year, and at what discount?
- What was PAR's latest cash position and runway?
Loading PAR…